<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03994640</url>
  </required_header>
  <id_info>
    <org_study_id>Silesian UM Cannabis</org_study_id>
    <nct_id>NCT03994640</nct_id>
  </id_info>
  <brief_title>Myorelaxant Effect of Cannabis Cream Topical Skin Application in Patients With TMD</brief_title>
  <official_title>Myorelaxant Effect of Cannabis Cream Topical Skin Application in Patients With Temporomandibular Disorders: a Randomized, Double-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Silesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Silesia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of myorelaxant effect of cannabis cream.compared to placebo cream in topical skin
      application in patients with TMD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cannabis sativa has a very wide application in various fields of medicine. In patients with
      temporomandibular disorder, especially with myofascial pain of masticatory muscles there is a
      special need to seek an effective pain therapy and muscle relaxing methods. Patients with TMD
      suffer from chronic pain and depression, cannabis topical skin application therapy seems
      promising in that field. Patients attending The Department of TMD in Zabrze, Polska were
      randomly divided into two groups: experimental and placebo. sEMG activity values were
      compared during 14 days therapy with cream. Positive results were obtained confirming the
      efficacy of the cannabis cream used in the study, compared to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">January 1, 2019</completion_date>
  <primary_completion_date type="Actual">October 1, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>two groups parallel study: experimental and control group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>double blind study: for patients and researchers</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of sEMG activity of masseter muscle</measure>
    <time_frame>14 days</time_frame>
    <description>Reduction in masseter muscle electromyographic activity</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Temporomandibular Disorder</condition>
  <condition>Myofascial Pain</condition>
  <condition>Cannabis</condition>
  <condition>Electromyography</condition>
  <arm_group>
    <arm_group_label>Cannabis cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cannabis cream topical skin application in experimental group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream topical skin application in control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Cannabis Cream</intervention_name>
    <description>Topical, bilateral skin application of cannabis cream with self-massage of masseter muscles</description>
    <arm_group_label>Cannabis cream</arm_group_label>
    <other_name>Cannabis cream topical skin application</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo Cream</intervention_name>
    <description>Topical, bilteral skin application of placebo cream with self-massage of masseter muscles</description>
    <arm_group_label>Placebo cream</arm_group_label>
    <other_name>Placeo cream topical skin application</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The inclusion criteria were as follows:

          1. Patient agreement to participate into the research study

          2. Age ≥22 and ≤ 27

          3. Good general health,

          4. Temporomandibular disorder-positive RDC/TMD examination for group Ia and Ib

          5. Presence of all teeth (with the exception of the third molars)

        The exclusion criteria were:

          1. Cannabis cream/ placebo cream allergy

          2. Hypersensitivity to substances to be used in the study

          3. Skin wounds with skin surface discontinuation

          4. Addiction to cannabis

          5. Patients being treated with analgesic drugs and/or drugs that affect muscle function

          6. Fixed or removable dental prosthesis

          7. Disease or autoimmune disorder associated with generalized muscular tension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>27 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of TMD Silesian Medical University</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler. 2004 Aug;10(4):417-24.</citation>
    <PMID>15327040</PMID>
  </reference>
  <reference>
    <citation>Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014 Apr 29;82(17):1556-63. doi: 10.1212/WNL.0000000000000363. Review.</citation>
    <PMID>24778283</PMID>
  </reference>
  <reference>
    <citation>Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP, List T, Svensson P, Gonzalez Y, Lobbezoo F, Michelotti A, Brooks SL, Ceusters W, Drangsholt M, Ettlin D, Gaul C, Goldberg LJ, Haythornthwaite JA, Hollender L, Jensen R, John MT, De Laat A, de Leeuw R, Maixner W, van der Meulen M, Murray GM, Nixdorf DR, Palla S, Petersson A, Pionchon P, Smith B, Visscher CM, Zakrzewska J, Dworkin SF; International RDC/TMD Consortium Network, International association for Dental Research; Orofacial Pain Special Interest Group, International Association for the Study of Pain. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Group†. J Oral Facial Pain Headache. 2014 Winter;28(1):6-27. doi: 10.11607/jop.1151.</citation>
    <PMID>24482784</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2019</study_first_posted>
  <last_update_submitted>June 20, 2019</last_update_submitted>
  <last_update_submitted_qc>June 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Silesia</investigator_affiliation>
    <investigator_full_name>Aleksandra Nitecka-Buchta</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>temporomandibular disorder</keyword>
  <keyword>Cannabis</keyword>
  <keyword>Electromyography</keyword>
  <keyword>Masticatory muscles</keyword>
  <keyword>Topical application</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temporomandibular Joint Disorders</mesh_term>
    <mesh_term>Temporomandibular Joint Dysfunction Syndrome</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

